2013-03-06 15:08:21 - Recently published research from Datamonitor, "Big Multinational Pharma in China", is now available at Fast Market Research

While losing a large chunk of revenue due to the patent cliff and while cutting research and sales headcounts at home and in other mature markets, big multinational pharmaceutical companies are looking for growth drivers elsewhere around the globe, particularly in emerging markets such as the BRICS (Brazil, Russia, India, China, and South Africa).

Report Scope

* This module presents an overview of big multinational pharma companies' history, operations, and key deals made in China.
* This module also shows big pharmaceutical companies' product portfolios and clinical development in China.

Report Hightlights

Robust economic growth, an aging population, changing dietary habits, and improvement of the healthcare infrastructure have made China one of the largest pharmaceutical markets, experiencing double-digit growth during the last decade.

A

unique product lifecycle, low operating costs, an improving intellectual property environment, and the introduction of an expedited approval process (for certain types of drugs) have also led to many foreign companies opening R&D centers in China and including the country in their global multicenter clinical trials.


Full Report Details at
- www.fastmr.com/prod/546445_big_multinational_pharma_in_china.asp ..


Reasons to Get this Report

* What is the nature of big pharmaceutical companies' presence in China?
* How have the companies built up to their present standing?

Report Table of Contents:

Table of Contents
Executive Summary
Strategic scoping and focus
Abbott
Company overview
Product portfolio and pipeline
Deals and strategic overview
AstraZeneca
Company overview
Product portfolio and pipeline
Deals and strategic overview
Bayer
Company overview
Product portfolio and pipeline
Deals and strategic overview
Boehringer Ingelheim
Company overview
Product portfolio and pipeline
Deals and strategic overview
Bristol-Myers Squibb
Company overview
Product portfolio and pipeline
Deals and strategic overview
Eli Lilly
Company overview
Product portfolio and pipeline
Deals and strategic overview
GlaxoSmithKline
Company overview
Product portfolio and pipeline
Deals and strategic overview
Johnson & Johnson
Company overview
Table of Contents
Company Analysis: Big Pharma Overview in China HC00257-005/Published 01/
Datamonitor. This report is a licensed product and is not to be photocopied Page
Product portfolio and pipeline
Deals and strategic overview
Merck & Co.
Company overview
Product portfolio and pipeline
Deals and strategic overview
Novartis
Company overview
Product portfolio and pipeline
Deals and strategic overview
Pfizer
Company overview
Product portfolio and pipeline
Deals and strategic overview
Roche
Company overview
Product portfolio and pipeline
Deals and strategic overview
Sanofi
Company overview
Product portfolio and pipeline
Deals and strategic overview
Bibliography
Journal papers
Websites

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.